MedPath

Examination about the effect of the cytapheresis combination therapy for patients with inflammatory bowel disease during biologics induction and maintenance administration.

Not Applicable
Conditions
Crohn&#39
s disease Ulcerative colitis
Registration Number
JPRN-UMIN000024793
Lead Sponsor
Shiga University of Medical Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

none

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
When we show the change of the anti-drug antibody with the CAP therapy, CAP therapy and anti-TNF antibody preparation combination may produce a synergistic effect.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath